SusmedTSE:4263 -0.36%69 Market Cap is 円14,180.9 Mil as of Jul. 06, 2026. GuruFocus rates TSE:4263 with a GF Score™ of 69/100 and a GF Value™ of 円974.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 692 Healthcare Providers & Services companies, Susmed ranks worse than 52.02% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Susmed's share price for the quarter that ended in Dec. 2025 was 円844. Susmed's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 16.9 Mil. Therefore, Susmed's market cap for the quarter that ended in Dec. 2025 was 円14,231.5 Mil.
Susmed's quarterly market cap
increased
from Mar. 2025 (円9,916.1 Mil) to Jun. 2025 (円10,275.2 Mil) and
increased
from Jun. 2025 (円10,275.2 Mil) to Dec. 2025 (円14,231.5 Mil).
Susmed's annual market cap
declined
from Jun. 2023 (円29,655.4 Mil) to Jun. 2024 (円10,055.4 Mil) but then
increased
from Jun. 2024 (円10,055.4 Mil) to Jun. 2025 (円10,275.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Susmed's Enterprise Value for Today is 円10,222.8 Mil.
Susmed (TSE:4263) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Susmed Market Cap Related Terms
Susmed Market Cap Historical Data
* Premium members only.
The historical data trend for Susmed's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4263 vs VEEV, BTSG, TEM: Market Cap Comparison
For the Health Information Services subindustry, Susmed's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Susmed Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Susmed's Market Cap distribution charts can be found below:
* The bar in red indicates where Susmed's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Susmed's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Susmed (TSE:4263) has a Market Cap of 円14,180.9 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Susmed and its competitors. According to the industry distribution chart, Susmed ranks #360 out of 692 companies in the Healthcare Providers & Services industry, placing it in the top 52%.
Is Susmed's Market Cap too high?
Susmed's current Market Cap is 円14,180.9 Mil. Based on the distribution chart, Susmed ranks #360 out of 692 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Susmed has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's Market Cap compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Susmed ranks #360 out of 692 companies for Market Cap. This places Susmed in the lower half of its industry. The industry median Market Cap is 98.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 98.70, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Susmed and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 98.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Susmed's current Market Cap is 円14,180.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円974.33, compared to a current price of 円841.00 — trading 13.7% below its estimated fair value. The current Market Cap is 円14,180.9 Mil. Susmed's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Susmed (TSE:4263), the current Market Cap is 円14,180.9 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Susmed (TSE:4263) Overvalued in 2026?
Based on GuruFocus' analysis, Susmed stock appears to be undervalued.
The current stock price of 円841.00 is trading 13.7% below its estimated GF Value™ of 円974.33.
GuruFocus considers Susmed to be Modestly Undervalued.
Key valuation signals for TSE:4263:
Market Cap: 円14,180.9 Mil
GF Value™: 円974.33 vs. price of 円841.00 (13.7% below fair value)
No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
69GF Score
Get the complete analysis for TSE:4263
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4263 has been successfully added to your 
